OncoMatch/Clinical Trials/NCT06607419
Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia
Is NCT06607419 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies Blinatumomab for b-cell lymphoblastic leukemia.
Treatment: Blinatumomab — The goal of this clinical trial is to evaluate the efficacy of Blinatumomab in pediatric patient with newly diagnosed acute B-Lymphoblastic leukemia with poor response to early chemotherapy, i.e. day 19 MRD ≥ 0.1% (low-risk) or day 19 MRD ≥ 0.01% (intermediate-risk). The main question is: • If the flow cytometric MRD negative (\<0.01%) rate and the NGS- MRD negative (\<0.0001%) rate at the end of induction for patients received Blinatumomab will be superior to historical control (D46MRD in the CCCG-ALL2020 protocol). Participants will: * Take 14 days full dose Blinatumomab; * With bone marrow evaluated before and after Blinatumomab treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Disease stage
Excluded: Stage INITIAL DIAGNOSIS OF HIGH RISK
Initial diagnosis of high risk [excluded]
Prior therapy
Cannot have received: glucocorticoid
Treated with glucocorticoids for ≥14 days within one month before enrollment
Cannot have received: ABL kinase inhibitor
ABL kinase inhibitors for > 7 days within one month before enrollment
Cannot have received: chemotherapy
Exception: except for emergency radiotherapy to relieve airway compression
any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)
Cannot have received: radiotherapy
Exception: except for emergency radiotherapy to relieve airway compression
any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify